Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical trials in which patients could receive a different treatment than capecitabine to reduce their risk of breast cancer relapse.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi potrójnie negatywny w stopniu zaawansowania I-III
- •Receptory hormonalne (estrogen i progesteron) poniżej 10%
- •Pozostałe guzy po co najmniej 4 cyklach chemioterapii przedoperacyjnej
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (ECOG 0-2)
- •Wyleczenie się z działań niepożądanych poprzedniego leczenia
- •Brak przerzutów (rozsiewu nowotworu)
- •Prawidłowe wyniki badań krwi, wątroby i nerek
✗ Disqualifies
- •Rak piersi z przerzutami
- •Brak operacyjnego usunięcia guza
- •Ciąża lub karmienie piersią
- •Nie ukończona radioterapia (jeśli była zaplanowana)
- •Zakażenie HIV lub aktywne zapalenie wątroby (B lub C)
- •Przyjmowanie innych badanych leków w ciągu ostatnich 4 tygodni
- •Niezdolność do połykania leków
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Stanford University
Stanford, United States
Trial contact
Vishal Joshi
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.